MediWound Reports Mixed 2025 Results Amid Key Clinical and Manufacturing Milestones
Event summary
- MediWound reported $17 million in revenue for 2025, down from $20.2 million in 2024, primarily due to U.S. government shutdown delays and lower product sales.
- The company's Phase III VALUE trial for EscharEx is progressing as planned, with key milestones expected by year-end 2026.
- Expanded NexoBrid manufacturing facility is now operational, increasing production capacity sixfold, pending regulatory approvals in 2026.
- MediWound reaffirmed its revenue guidance of $24–26 million for 2026, $32–35 million for 2027, and $50–55 million for 2028.
- Cash position strengthened to $53.6 million as of December 31, 2025, up from $43.6 million in 2024.
The big picture
MediWound's mixed 2025 results highlight the challenges of navigating regulatory and governmental hurdles while advancing its clinical and manufacturing capabilities. The company's strategic focus on enzymatic therapeutics for tissue repair positions it within the broader trend of non-surgical solutions in wound management. The success of its key growth drivers will be pivotal in determining its commercial readiness and scalability in the competitive biotechnology landscape.
What we're watching
- Regulatory Timelines
- The pace at which NexoBrid's expanded manufacturing facility receives regulatory approvals will determine its ability to meet global demand.
- Clinical Trial Success
- Whether the EscharEx Phase III VALUE trial meets its interim and enrollment completion milestones by year-end 2026 will be critical for its regulatory path.
- Revenue Growth Sustainability
- How MediWound's strategic growth drivers, including the EscharEx trial and NexoBrid adoption, will impact its ability to meet its reaffirmed revenue guidance for 2026–2028.
Related topics